EF
ANIK icon

Empirical Finance’s Anika Therapeutics ANIK Stock Holding History

Empirical Finance’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-105
Closed -$6K – 121
2016
Q4 		$6K Buy
+105
New +$4.86K ﹤0.01% 482

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Empirical Finance's ANIK Position: Q1 2017 in Review

Empirical Finance sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 105 shares — an estimated $6K sold.

Empirical Finance first reported a position in ANIK in Q4 2016 and held it in 1 quarter. The position peaked at $6K in Q4 2016. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

  • Empirical Finance reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Empirical Finance sold 105 Anika Therapeutics shares in Q1 2017, an estimated $6K.
  • Empirical Finance first reported a position in Anika Therapeutics in Q4 2016 and held it in 1 quarter.
  • Empirical Finance's Anika Therapeutics position peaked at $6K in Q4 2016.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on Empirical Finance's 13F filing for Q1 2017, filed 11 May 2017.